Irene Ghobrial, M.D.

Co-Author

Back to Details

This page shows the publications co-authored by Irene Ghobrial and Jorge Castillo.

Irene Ghobrial

Connection Strength

3.176

Jorge Castillo

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 Feb 20; 39(6):565-575.
View in: PubMed

Score: 0.240
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
View in: PubMed

Score: 0.231
Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702.
View in: PubMed

Score: 0.223
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in: PubMed

Score: 0.218
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
View in: PubMed

Score: 0.211
IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
View in: PubMed

Score: 0.191
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
View in: PubMed

Score: 0.190
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
View in: PubMed

Score: 0.184
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
View in: PubMed

Score: 0.176
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
View in: PubMed

Score: 0.175
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
View in: PubMed

Score: 0.173
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46.
View in: PubMed

Score: 0.168
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
View in: PubMed

Score: 0.166
Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
View in: PubMed

Score: 0.162
Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
View in: PubMed

Score: 0.160
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
View in: PubMed

Score: 0.155
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
View in: PubMed

Score: 0.059
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
View in: PubMed

Score: 0.052
Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
View in: PubMed

Score: 0.041

Connection Strength

The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.